Objective:To evaluate the diagnostic efficacy and practicality of the Jaundice color card (JCard) as a screening tool for neonatal jaundice.Methods:Following the standards for reporting of diagnostic accuracy studies (STARD) statement, a multicenter prospective study was conducted in 9 hospitals in China from October 2019 to September 2021. A total of 845 newborns who were admitted to the hospital or outpatient department for liver function testing due to their own diseases. The inclusion criteria were a gestational age of ≥35 weeks, a birth weight of ≥2 000 g, and an age of ≤28 days. The neonate′s parents used the JCard to measure jaundice at the neonate′s cheek. Within 2 hours of the JCard measurement, transcutaneous bilirubin (TcB) was measured with a JH20-1B device and total serum bilirubin (TSB) was detected. The Pearson′s correlation analysis, Bland-Altman plots and the receiver operating characteristic (ROC) curve were used for statistic analysis.Results:Out of the 854 newborns, 445 were male and 409 were female; 46 were born at 35-36 weeks of gestational age and 808 were born at ≥37 weeks of gestational age. Additionally, 432 cases were aged 0-3 days, 236 cases were aged 4-7 days, and 186 cases were aged 8-28 days. The TSB level was (227.4±89.6) μmol/L, with a range of 23.7-717.0 μmol/L. The JCard level was (221.4±77.0) μmol/L and the TcB level was (252.5±76.0) μmol/L. Both the JCard and TcB values showed good correlation ( r=0.77 and 0.80, respectively) and agreements (96.0% (820/854) and 95.2% (813/854) of samples fell within the 95% limits of agreement, respectively) with TSB. The JCard value of 12 had a sensitivity of 0.93 and specificity of 0.75 for identifying a TSB ≥205.2?μmol/L, and a sensitivity of 1.00 and specificity of 0.35 for identifying a TSB ≥342.0?μmol/L. The TcB value of 205.2?μmol/L had a sensitivity of 0.97 and specificity of 0.60 for identifying TSB levels of 205.2 μmol/L, and a sensitivity of 1.00 and specificity of 0.26 for identifying TSB levels of 342.0 μmol/L. The areas under the ROC curve (AUC) of JCard for identifying TSB levels of 153.9, 205.2, 256.5, and 342.0 μmol/L were 0.96, 0.92, 0.83, and 0.83, respectively. The AUC of TcB were 0.94, 0.91, 0.86, and 0.87, respectively. There were both no significant differences between the AUC of JCard and TcB in identifying TSB levels of 153.9 and 205.2 μmol/L (both P>0.05). However, the AUC of JCard were both lower than those of TcB in identifying TSB levels of 256.5 and 342.0 μmol/L (both P<0.05). Conclusions:JCard can be used to classify different levels of bilirubin, but its diagnostic efficacy decreases with increasing bilirubin levels. When TSB level are ≤205.2 μmol/L, its diagnostic efficacy is equivalent to that of the JH20-1B. To prevent the misdiagnosis of severe jaundice, it is recommended that parents use a low JCard score, such as 12, to identify severe hyperbilirubinemia (TSB ≥342.0 μmol/L).

BACKGROUND: To compare the efficacy and safety of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in Waldeyer's ring diffuse large B-cell lymphoma (WR-DLBCL) at a single institution. METHODS: This retrospective study included 115 newly diagnosed patients with WR-DLBCL, of whom 68 patients received R-CHOP, and 47 patients received DA-EPOCH-R as their first-line treatment. The baseline features of the two groups were well balanced using a 1:1 propensity score matching method, and a total of 84 cases were obtained, including respective 42 cases in the R-CHOP and DA-EPOCH-R groups, for further survival and prognosis analysis. The primary objectives included progression-free survival (PFS) and overall survival (OS). RESULTS: During a median follow-up of 45 months, there were nine (21.4%) deaths in the R-CHOP group and two (4.8%) in the DA-EPOCH-R group. Kaplan-Meier analysis showed statistically significant improvements in PFS and OS in patients with DA-EPOCH-R compared with those treated with R-CHOP (log-rank test, P  = 0.025 and P  = 0.035, respectively). The 2-year PFS and OS rates in the DA-EPOCH-R group were 90.1% (95% confidence interval [CI]: 81.4-99.8%) and 95.2% (95% CI: 89.0-100.0%), respectively, and 80.5% (95% CI: 69.3-93.6%) and 90.5% (95% CI: 52.8-99.8%) in the R-CHOP group. Patients without B symptoms and elevated lactate dehydrogenase levels had a higher PFS in the DA-EPOCH-R group, with P values of 0.038 (hazard ratio [HR]: 0.11; 95% CI: 0.01-0.88) and 0.042 (HR: 0.19; 95% CI: 0.04-0.94), respectively. There were no statistically significant differences in clinical responses and treatment-related toxicities between the two groups. CONCLUSION Compared with patients received R-CHOP, those treated by DA-EPOCH-R had superior PFS, OS, and controlled toxicity in patients with WR-DLBCL.
Humans ; Rituximab/therapeutic use* ; Vincristine/therapeutic use* ; Retrospective Studies ; Prednisone/therapeutic use* ; Etoposide/therapeutic use* ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Lymphoma, Large B-Cell, Diffuse/drug therapy* ; Cyclophosphamide/therapeutic use* ; Doxorubicin/therapeutic use*

Hypertrophic scar is the most common scar in clinic. Due to its high incidence, high rate of relapse and difficulty of complete removal, it has always been a big problem in burn and plastic surgery. In recent years, some scholars have found that botulinum toxin type A(BTX-A) can inhibit scar hyperplasia by reducing the tension around the wound, inhibiting the proliferation of fibroblasts, promoting their apoptosis, promoting the degradation of collagen fibers, reducing wound angiogenesis, reducing inflammation around the wound and other mechanisms. BTX-A has fewer adverse reactions and high safety. Additionally, its effect combined with triamcinolone acetonide and laser in treating scars is significant. Therefore, it has been widely used in the treatment of hypertrophic scars. In this paper, the research progress of BTX-A in the prevention and treatment of hypertrophic scar were reviewed in order to provide new ideas for the treatment of hypertrophic scar.

Hypertrophic scar is the most common scar in the clinic. Due to its high incidence, high rate of recurrence, and difficulty of complete removal, it has always been a major problem in the department of burn and plastic surgery. In recent years, some scholars have found that botulinum toxin type A(BTX-A) can inhibit scar hyperplasia by reducing the tension around the wound, inhibiting the proliferation of fibroblasts, promoting their apoptosis, promoting the degradation of collagen fibers, reducing wound angiogenesis, reducing inflammation around the wound and other mechanisms. BTX-A has fewer adverse reactions and high safety. Additionally, its effect combined with triamcinolone acetonide and laser in treating scars is significant. Therefore, it has been widely used in the treatment of hypertrophic scars. In this paper, the research progress of BTX-A in the prevention and treatment of hypertrophic scar was reviewed in order to provide new ideas for the treatment of hypertrophic scar.

Hypertrophic scar is the most common scar in clinic. Due to its high incidence, high rate of relapse and difficulty of complete removal, it has always been a big problem in burn and plastic surgery. In recent years, some scholars have found that botulinum toxin type A(BTX-A) can inhibit scar hyperplasia by reducing the tension around the wound, inhibiting the proliferation of fibroblasts, promoting their apoptosis, promoting the degradation of collagen fibers, reducing wound angiogenesis, reducing inflammation around the wound and other mechanisms. BTX-A has fewer adverse reactions and high safety. Additionally, its effect combined with triamcinolone acetonide and laser in treating scars is significant. Therefore, it has been widely used in the treatment of hypertrophic scars. In this paper, the research progress of BTX-A in the prevention and treatment of hypertrophic scar were reviewed in order to provide new ideas for the treatment of hypertrophic scar.

Hypertrophic scar is the most common scar in the clinic. Due to its high incidence, high rate of recurrence, and difficulty of complete removal, it has always been a major problem in the department of burn and plastic surgery. In recent years, some scholars have found that botulinum toxin type A(BTX-A) can inhibit scar hyperplasia by reducing the tension around the wound, inhibiting the proliferation of fibroblasts, promoting their apoptosis, promoting the degradation of collagen fibers, reducing wound angiogenesis, reducing inflammation around the wound and other mechanisms. BTX-A has fewer adverse reactions and high safety. Additionally, its effect combined with triamcinolone acetonide and laser in treating scars is significant. Therefore, it has been widely used in the treatment of hypertrophic scars. In this paper, the research progress of BTX-A in the prevention and treatment of hypertrophic scar was reviewed in order to provide new ideas for the treatment of hypertrophic scar.

Objective:To analyze the characteristics and citations of articles in Chinese Journal of Preventive Medicine from 2014 to 2017, and discuss the academic level and quality of the journal. Methods:All the literatures published in Chinese Journal of Preventive Medicine from 2014 to 2017 were retrieved through the Chinese Medical Citation index, and the citation frequency data in China′s core journals of science and technology from 2014 to 2018 was obtained through Institute of Scientific and Technical Information of China. The citation status of articles published in Chinese Journal of Preventive Medicine was statistically analyzed by the scientometric method. The main indicators included the citation rate of articles published in each year, the citation frequency of all articles, the citation status of individual papers and authors, the regional and high-yield institution distribution of cited authors, and the main citation journals. Results:From 2014 to 2017, a total of 929 articles were published in 19 columns of Chinese Journal of Preventive Medicine,and the number of each year was 253 (27.23%), 231 (24.87%), 224 (24.11%) and 221 (23.79%), respectively. The total number of published pages was 3 564, and the average number of articles was 3.45 pages. A total of 28 key topics have been published. The total citation was 3 861 times, with 4.16 times per paper. Among them, 161 papers were not cited，accounting for 17.33%. The maximum citation frequency of a single paper was 49 times. There were good citations in the columns of original article and methodology introduction. There was no correlation between fund project support and paper citation. But the cited rate (93.67%) and cited frequency of special issue ［ M ( P25, P75)=3 (1, 6)］ were higher compared with the cited rate (80.42%; χ 2=16.08, P<0.001) and cited frequency ［ M ( P25, P75)=2 (1, 6); Z=2.56, P=0.010] of free-lance articles. A total of 15 authors were cited more than 25 times, and 15 articles were cited more than 20 times. There were 213 institutions involved in the 768 cited papers, among which 12 institutions were cited more than 50 times. The authors of the cited papers were distributed in 28 provinces (autonomous regions, municipalities directly under the central government). From 2014 to 2018, a total of 281 journals cited the papers published in our journal, of which 12 journals cited more than 50 times. Conclusion:The quality of the literature in Chinese Journal of Preventive Medicine is high and the journal has a strong influence in the field of preventive medicine and public health in China. The editorial department should adjust the column setting timely, strengthen the planning of key topic selection and the solicitation and publicity of excellent papers, reduce the number of papers cited by zero, and further improve the influence of the magazine.

Objective:To analyze the characteristics and citations of articles in Chinese Journal of Preventive Medicine from 2014 to 2017, and discuss the academic level and quality of the journal. Methods:All the literatures published in Chinese Journal of Preventive Medicine from 2014 to 2017 were retrieved through the Chinese Medical Citation index, and the citation frequency data in China′s core journals of science and technology from 2014 to 2018 was obtained through Institute of Scientific and Technical Information of China. The citation status of articles published in Chinese Journal of Preventive Medicine was statistically analyzed by the scientometric method. The main indicators included the citation rate of articles published in each year, the citation frequency of all articles, the citation status of individual papers and authors, the regional and high-yield institution distribution of cited authors, and the main citation journals. Results:From 2014 to 2017, a total of 929 articles were published in 19 columns of Chinese Journal of Preventive Medicine,and the number of each year was 253 (27.23%), 231 (24.87%), 224 (24.11%) and 221 (23.79%), respectively. The total number of published pages was 3 564, and the average number of articles was 3.45 pages. A total of 28 key topics have been published. The total citation was 3 861 times, with 4.16 times per paper. Among them, 161 papers were not cited，accounting for 17.33%. The maximum citation frequency of a single paper was 49 times. There were good citations in the columns of original article and methodology introduction. There was no correlation between fund project support and paper citation. But the cited rate (93.67%) and cited frequency of special issue ［ M ( P25, P75)=3 (1, 6)］ were higher compared with the cited rate (80.42%; χ 2=16.08, P<0.001) and cited frequency ［ M ( P25, P75)=2 (1, 6); Z=2.56, P=0.010] of free-lance articles. A total of 15 authors were cited more than 25 times, and 15 articles were cited more than 20 times. There were 213 institutions involved in the 768 cited papers, among which 12 institutions were cited more than 50 times. The authors of the cited papers were distributed in 28 provinces (autonomous regions, municipalities directly under the central government). From 2014 to 2018, a total of 281 journals cited the papers published in our journal, of which 12 journals cited more than 50 times. Conclusion:The quality of the literature in Chinese Journal of Preventive Medicine is high and the journal has a strong influence in the field of preventive medicine and public health in China. The editorial department should adjust the column setting timely, strengthen the planning of key topic selection and the solicitation and publicity of excellent papers, reduce the number of papers cited by zero, and further improve the influence of the magazine.

Objective The present study aimed to establish a bone mineral density (BMD) reference database in China and to investigate the prevalence of osteoporosis in Chinese adults aged 50 years and older using dual energy X-ray absorptiometry (DXA). Method A total of 75321 examineers over 25 years old who underwent health checkups in 7 health check centers between 2008 and 2018 were included. All centers used a GE Lunar-DXA system to measure BMD of the lumbar spine (L1-L4), femoral neck, and total femur. The same European Spine Phantom (ESP) was used for scanning 10 times at every center, a regression equation was generated, and BMD data were cross-calibrated in each center. Peak BMD and standard deviation (SD) were identified according to 5-year age groups, and T scores were calculated based on the peak BMD and SD. Osteoporosis was defined according to the World Health Organization criteria. The prevalence of osteoporosis was standardized based on 2010 national census data for the Chinese population. Result The mean BMD values decreased with age, were highest in North China, followed by Northeast China, East China, and Southwest China, respectively, and increased with body mass index. Males aged 20-30 years and females aged 35-40 years had peak BMD values. Peak BMD values of the lumbar spine, femoral neck, and total femur were 1.09 g/cm2, 0.97 g/cm2, and 0.97 g/cm2 in males, and 1.11 g/cm2, 0.84 g/cm2, and 0.88 g/cm2 in females, respectively. Among all scanned sites, the prevalence of osteoporosis was highest in the femoral neck in males (4.58％) and in the lumbar spine in females (23.38％). The age-standardized prevalence of osteoporosis at any site was 6.46％ in males and 29.13％ in females aged 50 years and older. Based on the 2010 national census data, 10879115 males and 49286542 females currently have osteoporosis. Conclusion Mean BMD values varied according to geographic region, body mass index, age group, and sex in Chinese adults. The age-standardized prevalence of osteoporosis was 6.46％ in males and 29.13％ in females aged 50 years and older.

Objective To investigate the clinical outcomes of the surgical management for spinal tuberculosis with paraplegia retrospectively.Methods From March 2008 to April 2012,we retrospectively analyzed 78 patients with spinal tuberculosis combined with paraplegia.Among them,45 patients were male and 33 were female.The average age was 39.5(13 to 71) years.69 patients had focus-active paraplegia.41 patients had received chemotherapy before admissed to our hospital.They also received further standard chemotherapy for an average period of 2.3 (0 to 4) weeks after the admission.22 patients with complex complications (6 patients with active pulmonary tuberculosis,5 with tuberculous meningitis,7 with drug hepatitis,3 with kidney failure and 1 with unstable angina) received preoperative treatment for an average period of 4.5(3 to 8) weeks after the admission.6patients were managed with chemotherapy only.All 9 patients who had focus-healed paraplegia received surgical treatment after the admission immediately.Results All the patients were followed up clinically and radiologically for an average period of 31.4 (12 to 48) months.There was no recurrence of patients.At the final follow-up,all the patients had achieved rigid bony fusion.Both the VAS score and the Cobb angle had satisfactory improvement postoperatively and at the final follow-up.The neurological status began to improve 1-21 days after the operation.From 3 months postoperatively to the final follow-up,65 patients achieved complete recovery,7 partial recovery and 6 no recovery.The clinical outcomes for focus-active paraplegia were similar,while focushealed paraplegia had slower recovery and worse outcomes.Conclusion Patients with focus-active paraplegia combined with mild destruction and relative favourable neurological status could be treated conservatively.For patients with severe bony destruction and neurologic deficits (Frankel A-C,or combined with kyphosis),surgical treatment as early as possible is crucial to improve the neurologic status.If patients had contraindications,operation could be performed after the complications had been cured.However,the neurologic status improvement in focus-healed paraplegia is worse than focus-active paraplegia,suggesting that the reconstruction of spinal stability is important for initial treatment of spinal tuberculosis and children.